Vivelle-dot Patch, Extended Release
Product Images NDC 66758-145

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Vivelle-dot (NDC 66758-145). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fb4 (Fb)

Vivelle-Dot 0.075 mg/d transdermal patch packaging label from Sandoz Inc. The label indicates the patch delivers 0.075 mg/day of estradiol and is used twice weekly. The label includes patient instructions for patch application and removal, barcode, NDC number, and dosage strength prominently displayed.*

FDA Label Image

Fb1 (Fb1)

Packaging label for Vivelle-Dot patch, extended release estradiol transdermal system delivering 0.025 mg/day. The label shows the brand name Vivelle-Dot, active ingredient estradiol, dosage strength 0.025 mg/day, a twice weekly dosing instruction, and the labeler Sandoz Inc. It includes patient instructions for patch application and storage details.*

FDA Label Image

Fb2 (Fb2)

Vivelle-Dot estradiol transdermal system extended-release patch carton in 0.0375 mg/day strength. The purple and white packaging shows the brand and generic names, dosage form, delivery rate, and administration frequency as twice weekly. It includes patient instructions and the labeler is Sandoz Inc.*

FDA Label Image

Fb3 (Fb3)

Vivelle-Dot estradiol transdermal system 0.05 mg/day extended-release patch packaging. The rectangular box is purple with white text, indicating the patch delivers 0.05 mg/day and is for twice weekly use. Labeler is Sandoz Inc. Instructions for use are printed inside the package flap, including steps for application. The package contains 8 systems and is labeled Rx only.*

FDA Label Image

Fb5 (Fb5)

Packaging label for Vivelle-Dot 0.1 mg/d estradiol transdermal system patch by Sandoz Inc. The label displays dosing instructions, including patch application directions, warnings for prescription use only, and labeling indicating it delivers 0.1 mg per day. The design features purple and beige colors with the Vivelle-Dot logo and regulatory information.*

FDA Label Image

Estradiolstructuralformula (Vivelledot01)

Chemical structure of estradiol, the active ingredient in Vivelle-Dot. The diagram shows the molecular configuration with hydroxyl groups and carbon rings characteristic of this hormone.*

FDA Label Image

Vivelledotlayerimage (Vivelledot02)

Chemical structure of estradiol, the active ingredient in Vivelle-Dot transdermal patches. The diagram shows the molecular arrangement typical of estradiol, a synthetic form of the hormone estrogen used in hormone therapy.*

FDA Label Image

Figure1 (Vivelledot03)

A line graph showing estradiol concentration (pg/mL) over time (days) for different Vivelle-Dot transdermal patch strengths: 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day. The graph compares the pharmacokinetic profiles of these extended-release estradiol doses over a 4-day period.*

FDA Label Image

Figure2 (Vivelledot04)

A bar graph showing mean (SD) reduction from baseline at Weeks 4, 8, and 12 comparing Vivelle-Dot 0.0375 mg/day transdermal patch to placebo. The vertical axis represents reduction from baseline, with Vivelle-Dot bars consistently lower than placebo bars. Sample sizes and SD values are labeled for each group at each time point. A note indicates statistically significant differences (p<0.05) between Vivelle and placebo at all weeks.*

FDA Label Image

Figure3 (Vivelledot05)

A line graph showing percent change from baseline over treatment duration (weeks 26 to 104) for Vivelle-Dot estradiol patches at four dosages (.025, .0375, .05, .1 mg/day) and a placebo. The graph plots upward trends for all Vivelle-Dot dosages, with the highest dosage (.1 mg/day) showing the greatest increase, while placebo shows a downward trend.*

FDA Label Image

Figure4 (Vivelledot06)

A line chart showing percent change from baseline over treatment duration (weeks 26, 52, 78, and 104) for Vivelle-Dot estradiol transdermal patches at doses of 0.1 mg/day, 0.05 mg/day, 0.0375 mg/day, 0.025 mg/day, and placebo. The 0.1 mg/day group shows a consistent positive change, while placebo shows a decline. Statistical significance (p<0.05) is indicated comparing Vivelle-Dot doses to placebo at multiple time points.*

FDA Label Image

Ifuimage1 (Vivelledot07)

Vivelle-Dot estradiol transdermal system patch label showing dosing schedule options for changing the patch every two days. The options include Sun/Wed, Mon/Thu, Tue/Fri, Wed/Sat, Thu/Sun, Fri/Mon, and Sat/Tue. The label displays the product name and indicates it is a patch for hormone replacement therapy by Sandoz Inc.*

FDA Label Image

Ifuimage2 (Vivelledot08)

An illustration showing a hand applying an extended-release transdermal patch to the abdomen. The illustration emphasizes proper placement of the patch on the skin for the drug Vivelle-Dot estradiol patch.*

FDA Label Image

Ifuimage3 (Vivelledot09)

FDA Label Image

Ifuimage4 (Vivelledot10)

An instructional illustration showing hands removing a protective backing from a transdermal patch, demonstrating the correct method to prepare the patch for application on the skin.*

FDA Label Image

Ifuimage5 (Vivelledot11)

An instructional illustration showing a pair of hands peeling apart the backing of a Vivelle-Dot estradiol transdermal patch, extended-release dosage form. This diagram visually guides users on how to properly remove the protective liner before application.*

FDA Label Image

Ifuimage6 (Vivelledot12)

An instructional illustration showing a hand applying a Vivelle-Dot estradiol transdermal patch to the lower abdominal area of the body.*

FDA Label Image

Ifuimage7 (Vivelledot13)

An instructional illustration showing hands applying a patch to the upper arm, demonstrating the proper placement of the Vivelle-Dot estradiol extended release transdermal patch on the skin.*

FDA Label Image

Ifuimage8 (Vivelledot14)

An instructional illustration depicting hands applying a Vivelle-Dot estradiol transdermal extended release patch to the skin. The drawing focuses on the correct placement method of the patch on the skin surface.*

FDA Label Image

Ifuimage9 (Vivelledot15)

An instructional line drawing showing an extended-release transdermal patch applied to the back of a person's hand or wrist, likely demonstrating correct patch placement for Vivelle-Dot estradiol skin patches.*

FDA Label Image

Ifuimage10 (Vivelledot16)

An instructional illustration showing a hand applying a small rectangular adhesive patch to the lower abdomen, demonstrating the placement of a transdermal patch on the skin. The patch likely represents the Vivelle-Dot estradiol extended-release transdermal patch.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.